Last reviewed · How we verify
Diquafosol ophthalmic sodium solution 3%
Diquafosol is a P2Y2 purinergic receptor agonist that stimulates secretion of mucin and aqueous fluid from conjunctival and lacrimal glands to increase tear production.
Diquafosol is a P2Y2 purinergic receptor agonist that stimulates secretion of mucin and aqueous fluid from conjunctival and lacrimal glands to increase tear production. Used for Dry eye disease (keratoconjunctivitis sicca).
At a glance
| Generic name | Diquafosol ophthalmic sodium solution 3% |
|---|---|
| Sponsor | Taejoon Pharmaceutical Co., Ltd. |
| Drug class | P2Y2 receptor agonist |
| Target | P2Y2 purinergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Diquafosol sodium activates P2Y2 receptors on the ocular surface, triggering increased mucin secretion from goblet cells and aqueous tear secretion from lacrimal glands. This mechanism addresses the underlying pathophysiology of dry eye disease by promoting endogenous tear production rather than simply lubricating the eye surface.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Ocular discomfort
- Taste perversion
Key clinical trials
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
- Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
- Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye (NA)
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients (PHASE3)
- To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment Pattern (NA)
- Diquafosol Ophthalmic Solution for Dry Eye Symptoms (NA)
- The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye (PHASE4)
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: